Inquis Medical, Inc., a privately held clinical stage medical device company based in Silicon Valley, has announced it has secured $75.0 million in new funding from investors. This significant capital infusion will support the company's ongoing efforts to develop and commercialize innovative solutions for the management of venous thromboembolic diseases. The investment marks a pivotal moment for Inquis Medical as it progresses its proprietary technology through critical development phases.
The company's legacy is built on decades of experience in developing, launching, and supporting novel, physician-tested medical devices designed to address unmet needs in healthcare. Inquis Medical's core focus is on improving outcomes for patients suffering from venous thromboembolic diseases. Its innovative team has developed a proprietary next-generation thrombectomy technology, which aims to enable an efficient single-pass thrombectomy procedure with minimal blood loss, potentially offering a significant advancement in patient care.
This $75.0 million investment will be strategically deployed to accelerate the clinical development and regulatory pathway for its advanced thrombectomy technology. The funds are earmarked for expanding research and development initiatives, conducting further clinical trials, and scaling operations as the company moves closer to potential market introduction. This funding round underscores investor confidence in Inquis Medical's technology and its potential to make a substantial impact on patient treatment paradigms.
The capital raised is crucial for Inquis Medical as it continues its mission to bring physician-tested devices to market that offer long-lasting impact. The company remains committed to its innovative approach, aiming to provide effective and efficient solutions that improve patient outcomes and address critical gaps in current medical device offerings for venous thromboembolic conditions. With this funding, Inquis Medical is positioned to accelerate its mission of bringing innovative solutions to patients and healthcare providers, aiming for a long-lasting impact in the medical device sector.
